Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00143286 · ClinicalTrials.gov registry record · Phase 3

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

A Phase 3 study of Smoking Cessation, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
2,000
Enrollment target
20
Study locations

NCT00143286 is a Phase 3 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 2,000 participants, above the 464-participant average among 188 other Smoking Cessation trials with a reported enrollment target (331% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00143286, a Phase 3 study of Smoking Cessation, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
2,000 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.

Conditions Studied

Smoking Cessation

Interventions

  • DRUG varenicline (CP-526,555)

Study Locations (20)

Other

  • Pfizer Investigational Site - Prague
  • Pfizer Investigational Site - Aarhus C
  • Pfizer Investigational Site - Frederikssund
  • Pfizer Investigational Site - Bergen
  • Pfizer Investigational Site - Hønefoss
  • Pfizer Investigational Site - Oslo
  • Pfizer Investigational Site - Gothenburg

Ontario

  • Pfizer Investigational Site - Ottawa
  • Pfizer Investigational Site - Toronto

California

  • Pfizer Investigational Site - Santa Ana

Florida

  • Pfizer Investigational Site - West Palm Beach

Kentucky

  • Pfizer Investigational Site - Lexington

Ohio

  • Pfizer Investigational Site - Mogadore

Texas

  • Pfizer Investigational Site - Dallas

Washington

  • Pfizer Investigational Site - Seattle

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2003-04
Est. Completion 2005-03
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00143286

The ClinicalTrials.gov registry entry for NCT00143286 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 464-participant average among 188 other Smoking Cessation trials with a reported enrollment target (331% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which varenicline (CP-526,555) is the first listed.

NCT00143286 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Ontario, California.

Frequently Asked Questions

What is clinical trial NCT00143286 about?

NCT00143286 is a clinical study titled "A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation". The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.

What is the current status of trial NCT00143286?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2003-04. Estimated completion is 2005-03.

What conditions does trial NCT00143286 study?

This clinical trial studies the following conditions: Smoking Cessation.

What interventions are being tested in trial NCT00143286?

The interventions under investigation include: varenicline (CP-526,555) (DRUG).

Who is sponsoring clinical trial NCT00143286?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00143286 being conducted?

This trial has 20 study locations across California, Florida, Kentucky, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Smoking Cessation

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.